Business
American Diversified Holdings Corporation Receives $5,000,000 (Five Million) Financing Commitment from an Institutional Investment Fund
American Diversified Holdings Corporation Receives $5,000,000 (Five Million) Financing Commitment from an Institutional Investment Fund.
About this update from American Diversified Holdings Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n American Diversified Holdings Corporation Receives $5,000,000 (Five Million) Financing Commitment from an Institutional Investment Fund\r\n \r\n \r\n\r\n\r\nAmerican Diversified Holdings Corporation Receives $5,000,000 (Five Million) Financing Commitment from an Institutional Investment Fund\r\n\r\n\r\n\r\nNewsfile Corp.\r\n\r\n\r\nNewsfile Corp\r\n\r\n\r\nDel Mar, California--(Newsfile Corp. - October 16, 2025) - American Diversified Holdings Corporation (OTCID: ADHC) announced today that a prominent institutional investment fund has committed to providing up to $5,000,000 (Five Million Dollars) in financing to the company.\r\nThe terms of the agreement provide for investment tranches to be delivered to ADHC based upon a (\"Use Of Funds\"). The proceeds of this investment are earmarked for the research and development of the GlucoGuard project and for general corporate purposes. Additionally, this capital will further our collaboration efforts with DexCom, our Continuous Glucose Monitoring (CGM) development partner.\r\nAfter lengthy interactions with the ADHC Medical Advisory Board (MAB) and the Food and Drug Administration (FDA), a two prong SLEEP STUDY was requested that will satisfy concerns as to safety and efficacy of the device.\r\nArete Bioscience and Dr. Kunal Sur PhD has presented a Scope of Work (SOW) proposal including \"Use of Funds\" in coordination with a noted sleep laboratory that is designed to specifically meet the FDA's concerns.\r\nThe major components of the Breakthrough Device Application Designation have been positively reviewed by the FDA as to the \"UNMET NEED\" and GlucoGuard's ability to assist patients.\r\n\"This investment commitment will provide the capital that will launch ADHC into a new phase of enhanced valuation. Due to our incredible team, we have advanced GlucoGuard toward FDA approval in rapid time with minimal capital,\" commented ADHC. \"Helping Type 1 Diabetics with managing hypoglycemic events is the critical mission. The peace of mind of knowing that during sleep, a potentially life-threatening event can be averted and managed will clearly improve patients' lives,\" concluded ADHC.\r\n\r\nContact: Phone: 817-52-0057\r\nwww.GlucoGuardSleep.com\r\nwww.UniversalWellnessAI.com\r\nJohn Cacchioli, CEO American Diversified Holdings Corporation\r\nTelephone: (212) 537-5900\r...